Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2B | Q13224 | 5/20 | 0.36 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | MAOB | P27338 | 1/20 | 0.35 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.35 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10006357 | 0.88 | GRIN2B (0.37) | GRIN2BMAOBGRIN1SMN1; SMN2 | |
| SCHEMBL10006583 | 0.86 | ALDH1A1 (0.36) | GRIN2BMAOBGRIN1SMN1; SMN2 | |
| SCHEMBL10007280 | 0.85 | TSHR (0.35) | GRIN2BADORA1KMT2AMAOBADORA2A | |
| SCHEMBL10006348 | 0.83 | CYP3A4 (0.38) | KMT2AL3MBTL1MEN1KDM4ESMN1; SMN2 | |
| SCHEMBL10007296 | 0.78 | GRIN2B (0.43) | GRIN2BGRIN1 | |
| SCHEMBL10006678 | 0.78 | GRIN2B (0.37) | GRIN2BMAOBADORA2AGRIN1 | |
| SCHEMBL10261397 | 0.78 | TSHR (0.41) | KMT2AADORA2AMEN1SMN1; SMN2 | |
| SCHEMBL10006797 | 0.77 | ATM (0.39) | GRIN2BKMT2AMAOBGRIN1 | |
| SCHEMBL10261255 | 0.77 | PREP (0.36) | GRIN2BKMT2AHRH3MEN1KDM4E | |
| SCHEMBL10007381 | 0.77 | TSHR (0.38) | GRIN2BGRIN1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2476682-B1 | 8-OXODIHYDROPURINE DERIVATIVE | SUMITOMO DAINIPPON PHARMA CO LTD (JP) | 2017-04-26 | — | — | EP | disclosed |
| US-8735406-B2 | 8-oxodihydropurine derivative | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2014-05-27 | — | — | US | disclosed |
| EP-2476682-A1 | 8-OXODIHYDROPURINE DERIVATIVE | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2012-07-18 | — | — | EP | disclosed |
| US-20120172347-A1 | 8-OXODIHYDROPURINE DERIVATIVE | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2012-07-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120172347-A1 | 8-OXODIHYDROPURINE DERIVATIVE | FAAH, FAAH2, TPMT | GRIN2B 635/4885ADORA1 32/4885KMT2A 769/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.